Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer
- PMID: 20168320
- DOI: 10.1038/nrc2804
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer
Erratum in
- Nat Rev Cancer. 2010 Mar;10(3). doi: 10.1038/nrc2825
Abstract
The year 2009 marked the fiftieth anniversary of the first successful allogeneic haematopoietic stem cell transplant (HSCT). The field of HSCT has pioneered some of the most exciting areas of research today. HSCT was the original stem cell therapy, the first cancer immune therapy and the earliest example of individualized cancer therapy. In this Timeline article we review the history of the development of HSCT and major advances made in the past 50 years. We highlight accomplishments made by researchers who continue to strive to improve outcomes for patients and increase the availability of this potentially life-saving therapy for patients with otherwise incurable malignancies.
Similar articles
-
60 Years Young: The Evolving Role of Allogeneic Hematopoietic Stem Cell Transplantation in Cancer Immunotherapy.Cancer Res. 2021 Sep 1;81(17):4373-4384. doi: 10.1158/0008-5472.CAN-21-0301. Epub 2021 Jun 9. Cancer Res. 2021. PMID: 34108142 Free PMC article. Review.
-
EBMT activity survey 2004 and changes in disease indication over the past 15 years.Bone Marrow Transplant. 2006 Jun;37(12):1069-85. doi: 10.1038/sj.bmt.1705377. Bone Marrow Transplant. 2006. PMID: 16757972
-
Hematopoietic cell transplantation: five decades of progress.Arch Med Res. 2003 Nov-Dec;34(6):528-44. doi: 10.1016/j.arcmed.2003.09.010. Arch Med Res. 2003. PMID: 14734093 Review.
-
Historical markers in the development of allogeneic hematopoietic cell transplantation.Biol Blood Marrow Transplant. 1999;5(6):341-6. doi: 10.1016/s1083-8791(99)70010-8. Biol Blood Marrow Transplant. 1999. PMID: 10595811 Review. No abstract available.
-
Activity survey and historical perspective of autologous stem cell transplantation in Europe.Semin Hematol. 2007 Oct;44(4):220-6. doi: 10.1053/j.seminhematol.2007.09.001. Semin Hematol. 2007. PMID: 17961720
Cited by
-
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy.Immunotargets Ther. 2014 Dec 4;3:151-65. doi: 10.2147/ITT.S37790. eCollection 2014. Immunotargets Ther. 2014. PMID: 27471706 Free PMC article. Review.
-
Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.PLoS One. 2012;7(1):e30897. doi: 10.1371/journal.pone.0030897. Epub 2012 Jan 27. PLoS One. 2012. PMID: 22303468 Free PMC article.
-
SLAMF6 in health and disease: Implications for therapeutic targeting.Clin Immunol. 2019 Jul;204:3-13. doi: 10.1016/j.clim.2018.10.013. Epub 2018 Oct 23. Clin Immunol. 2019. PMID: 30366106 Free PMC article. Review. No abstract available.
-
Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: the experiences of more than 25 years.Clin Exp Immunol. 2011 Mar;163(3):284-95. doi: 10.1111/j.1365-2249.2010.04312.x. Clin Exp Immunol. 2011. PMID: 21303358 Free PMC article. Review.
-
Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2rγ(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease.Clin Exp Immunol. 2011 Nov;166(2):269-80. doi: 10.1111/j.1365-2249.2011.04462.x. Clin Exp Immunol. 2011. PMID: 21985373 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous